Private foundation
SAN ANTONIO, TXEIN
The funder's latest Form 990-PF says it accepts applications. Read the instructions below before you write.
Application policy: Accepts applications, as stated on the FY2024 return.
These lines count this foundation's own Form 990-PF returns that the IRS has published as data. An amended return replaces its original. They describe past returns only.
This is a count from past returns. It does not say the foundation will consider a new request. How it is counted: names are compared as written on the returns, without "The" at the start, without endings such as "Inc" or "LLC", and without spaces and punctuation. A recipient also counts as already listed when our records link it to the same organization as an earlier recipient, or when its name is almost the same as an earlier name (a trigram similarity of 0.8 or more, where 1 means identical). The state on the grant row is not compared. Grants that the foundation marked as paid to an individual, such as a scholarship, are left out of both numbers, and no count is shown when most of its grants are marked that way. A person whom the foundation did not mark as an individual is still counted as a recipient. A recipient can still look new when its name is written very differently from year to year, and two different recipients with almost the same name can be counted as one.
Application guidance comes from the funder's own Form 990-PF, Part XV (the section where a private foundation says how to apply), shown as filed. It is the funder's words, not ours. These fields are free text and the IRS form cuts them short. Filers sometimes put whole sentences in the contact-name box. Shown exactly as filed.
No parsed e-filed return is on record for this organization yet, so year-by-year financials are not available.
Asset, income and revenue figures come from the IRS master file (the IRS Exempt Organizations Business Master File), a coarse annual extract. Year-by-year figures appear once the organization's e-filed returns are in the database.
Recipient focus areas
Where recipients are
Based on the 1% of grant rows we could match to an organization record. The rest stay as reported. The IRS assigns the NTEE category when it grants exemption. It often reflects the original filing, not today's giving.
| Recipient | Purpose | Amount | Year | Source |
|---|---|---|---|---|
| UTHSC-SA OFFICE OF THE PRESIDENTSAN ANTONIO, TX | TARGETED DELIVERY OF DRUGS TO REPAIRINJURED NERVES TO TREATCOGNITIVE DECLINE | $99,800 | 2019 | |
Recipients are shown as the funder wrote them on the return. A recipient with a link was matched to an organization record; the rest stay as reported and are never guessed.
| Name | Title | Hours / week | Compensation |
|---|---|---|---|
| William C Owens Jr Trustee | TRUSTEE | 1.00 | $0 |
From the officer list on the latest e-filed return. Compensation is as reported there; a blank means the return carries no figure.
| U T HEALTH - SAN ANTONIO (UTHSC-SA)SAN ANTONIO, TX |
| INCREASING THE EFFECTIVENESS OF B1 & C3AS A POTENTIAL TREATMENTOF BREAST CANCER AND MYELOMA |
| $99,604 |
| 2020 |
| U T HEALTH - SAN ANTONIO (UTHSC-SA)SAN ANTONIO, TX | ANALYZE METHYLENE BLUE,A SAFE DRUG, TO TREAT PARKINSON'SAND AGE-RELATED COGNITIVE DECLINE | $99,494 | 2020 |
| UTHSC-SA OFFICE OF THE PRESIDENTSAN ANTONIO, TX | INCREASING THE EFFECTIVENESS OF B1 AS A POTENTIAL TREATMENT OF BREAST CANCER AND MYELOMA | $99,177 | 2019 |
| UTHSC-SA OFFICE OF THE PRESIDENTSAN ANTONIO, TX | ROLE OF MYELOID DERIVEDSUPPRESSOR CELLSIN WOUND HEALING | $98,956 | 2019 |
| UTHSC-SA OFFICE OF THE PRESIDENTSAN ANTONIO, TX | EFFECTIVENESS OF COGNITIVE BEHAVIORAL THERAPY COMBINED WITH MEDICATIONSTO TREAT DEPRESSION CAUSED BY STRESS | $98,928 | 2019 |
| U T HEALTH - SAN ANTONIO (UTHSC-SA)SAN ANTONIO, TX | USING THE SYNTHETIC PROTEOLYTICDT2216 TO TARGET BCL-XL IN LYMPHOMA(OVERCOMING CHEMOTHERAPY RESISTANCE) | $98,804 | 2020 |
| UTHSC-SA OFFICE OF THE PRESIDENTSAN ANTONIO, TX | ANALYZE METHYLENE BLUE, A SAFEDRUG, TO TREAT PARKINSON'SAND AGE-RELATED COGNITIVE DECLINE | $98,308 | 2019 |
| U T HEALTH - SAN ANTONIO (UTHSC-SA)SAN ANTONIO, TX | USE OF PALMATINE TO ENHANCEGEMCITABINE TREATMENT OFPANCREATIC CANCER | $97,750 | 2020 |
| UTHSC-SA OFFICE OF THE PRESIDENTSAN ANTONIO, TX | USE OF PALMATINE TO ENHANCEGEMCITABINE TREATMENT OF PANCREATIC CANCER | $96,810 | 2019 |
| U T HEALTH - SAN ANTONIO (UTHSC-SA)SAN ANTONIO, TX | RESEARCH TREATING ALZHEIMER'SWITH AN ANTIBODY TO REMOVETAU OLIGOMERS | $95,264 | 2020 |
| U OKLAHOMA FOUNDATIONNORMAN, OK | DETERMINE WHETHER SILENCING ZIP4ENHANCES THE EFFECTIVENESS OFCHEMOTHERAPY TREATMENT OF BRAIN CANCER | $95,000 | 2022 |
| U OKLAHOMA FOUNDATIONNORMAN, OK | DETERMINE WHETHER SILENCING ZIP4ENHANCES THE EFFECTIVENESS OFCHEMOTHERAPY TREATMENT OF BRAIN CANCER | $95,000 | 2023 |
| U OKLAHOMA HEALTH SCI CENOKLAHOMA CITY, OK | DETERMINE WHETHER SILENCING ZIP4ENHANCES THE EFFECTIVENESS OFCHEMOTHERAPY TREATMENT OF BRAIN CANCER | $95,000 | 2021 |
| UTHSC-SA OFFICE OF THE PRESIDENTSAN ANTONIO, TX | RESEARCH MIR-124,-128, AND -137 TO DEVELOP METHODS TO PREVENT BRAIN DEGENERATION | $93,525 | 2019 |
| U OKLAHOMA HEALTH SCI CENOKLAHOMA CITY, OK | DETERMINE WHETHER SILENCING ZIP4ENHANCES THE EFFECTIVENESS OFCHEMOTHERAPY TREATMENT OF BRAIN CANCER | $90,000 | 2020 |
| UTHSC-SA OFFICE OF THE PRESIDENTSAN ANTONIO, TX | ANALYSIS OF OVARIAN CANCER TODEVELOP TREATMENTS | $85,000 | 2019 |
| U T HEALTH - SAN ANTONIO (UTHSC-SA)SAN ANTONIO, TX | ANALYSIS OF CERTAIN TYPES OFOVARIAN CANCER TO DEVELOPRELEVANT TREATMENTS | $85,000 | 2020 |
| U OKLAHOMA HEALTH SCI CENTEROKLAHOMA CITY, OK | DETERMINING WHETHER SILENCING ZIP4 ENHANCES THE EFFECTIVEHESS OFCHEMOTHERAPY IN BRAIN CANCER TREATMENT | $80,000 | 2019 |
| UTHSC-SA OFFICE OF THE PRESIDENTSAN ANTONIO, TX | RESEARCH TREATING ALZHEIMER'SWITH AN ANTIBODY TO REMOVETAU OLIGOMERS | $78,017 | 2019 |
| HOUSTON METHODIST HOSPITAL FOUNDATIONHOUSTON, TX | PROGNOSTIC VALUE OF SPECIFICITYPROTEINS IN GASTROINTESTINALCANCERS (COLON & PANCREATIC CANCERS) | $75,000 | 2020 |
| U NORTH TX HEALTH SCI CENFORT WORTH, TX | NEUROPROTECTIVE MECHANISMS OF TRICHOSTATIN-A (TSA) IN 3XTG-MOUSEMODEL OF ALZHEIMER'S DISEASE | $70,803 | 2019 |
| UTHSC-SA OFFICE OF THE PRESIDENTSAN ANTONIO, TX | IDENTIFYING MARKERS FOR EARLY DIAGNOSIS OFPANCREATIC CANCER | $70,000 | 2019 |
| U T HEALTH - SAN ANTONIO (UTHSC-SA)SAN ANTONIO, TX | DEVELOP METHOD OF DIAGNOSISOF PANCREATIC CYSTIC LESIONS | $65,000 | 2020 |
| U T HEALTH - SAN ANTONIO (UTHSC-SA)SAN ANTONIO, TX | IDENTIFYING MICRORNA BY TISSUEOF ORIGIN (CANCEROUS ORHEALTHY) FOR EARLY CANCER DIAGNOSIS | $53,609 | 2020 |
Nearest by size, location and giving pattern in the database. Geography weighs heavily. Treat it as a starting list, not a ranking of fit.